HCPCS code J1953 – Injection, levetiracetam

Key takeaways

HCPCS Code J1953 describes an injection of levetiracetam (Keppra IV), billed at 10 mg per unit under HCPCS Level II J-codes.

Bill 1 unit per 10 mg administered, so a 500 mg dose equals 50 units. Undercounting units is the most common claim error for this code.

Medicare reimburses J1953 at Average Sales Price (ASP) plus 6%, updated quarterly by CMS. Check the current quarter’s ASP pricing file before billing.

CMS has required a wastage modifier on single-dose vial drugs since October 1, 2023. Use JW for a discarded amount, or JZ when the full vial is given.

Practice management software like Pabau keeps the treatment note and the invoice on one patient record, so each claim’s documentation stays together.

HCPCS Code J1953: definition and code details

HCPCS Code J1953 is a Level II J-code maintained by the Centers for Medicare and Medicaid Services (CMS). It covers one unit of levetiracetam injection, equivalent to 10 mg of the drug.

The J-series of HCPCS Level II covers drugs given by injection in physician offices, outpatient facilities, and infusion centers. CMS updates the code set through the annual HCPCS release cycle. Verify the code’s active status each year against the AAPC HCPCS code lookup or the CMS HCPCS release files.

Drug overview: levetiracetam (Keppra)

Levetiracetam is an anticonvulsant approved by the FDA for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. The intravenous formulation, Keppra IV, is indicated when oral administration is temporarily not feasible. Supporting medical necessity for J1953 claims requires linking the claim to a diagnosis that reflects one of these approved indications.

The G40 epilepsy series in ICD-10-CM represents the most commonly paired diagnosis codes. Payers expect an ICD-10 code that demonstrates clinical appropriateness at the time of administration. Off-label use may affect coverage, so document the clinical rationale in the patient record when the indication falls outside the standard G40 grouping.

Billing units: how to calculate the correct units for J1953

J1953 is billed at 1 unit per 10 mg administered. Divide the total milligrams administered by 10 to get the unit count.

Practices go wrong by rounding, by failing to convert from mL to mg, or by not counting partial vials. Each of those errors produces a unit count that does not match the drug administered, which triggers claim edits or denials.

Always document the exact milligrams administered before you calculate units for the claim. If a vial holds more than the administered dose and the remainder is discarded, bill only the units administered. Report the discarded units on a separate line with modifier JW. Check each payer’s wastage policy before submitting, since Medicare and commercial rules differ.

J1953 Medicare reimbursement and fee schedule

Medicare reimburses J1953 under the Average Sales Price (ASP) methodology, as established under Section 1847A of the Social Security Act. The payment rate is set at ASP plus 6%, updated quarterly via CMS drug payment files. Because ASP reflects manufacturer-reported average sales prices and changes every quarter, any rate you reference today may be outdated by the next filing period.

The rates live in the CMS ASP drug pricing files, published each quarter. Use the quarterly ASP pricing file rather than the Physician Fee Schedule lookup, which does not carry drug pricing. Verify the rate applicable to the date of service, not the date of billing.

Commercial payer rates for J1953 are contract-specific and can differ substantially from Medicare’s ASP methodology. Some plans reimburse at a percentage of Medicare, others at a flat negotiated rate.

Medicaid reimbursement is state-administered, so a practice in Texas may receive a different rate than one in New York. Verifying the patient’s benefit before each infusion also shows whether the plan covers the drug under the medical benefit or the pharmacy benefit.

Applicable billing modifiers for J1953

Modifiers signal to payers how a drug was administered, who administered it, or whether special circumstances apply. Using the wrong modifier, or omitting one required by a payer, is one of the fastest ways to generate a denial. Always verify modifier requirements with each payer before submitting, as usage policies vary.

The JA modifier is the most clinically relevant for J1953, since levetiracetam is almost always given intravenously. Many payers require it to distinguish the IV formulation from an oral route billed under a different code.

JW and JZ sit alongside it, and one of the two belongs on every single-dose vial claim. Modifier policies are not universal across Medicare Administrative Contractors (MACs) and commercial plans, so verify each payer’s rules. Getting modifier selection right before submission is the first step in denial management.

ICD-10 codes commonly billed with J1953

Every J1953 claim needs a supporting ICD-10 diagnosis code that establishes medical necessity. The G40 series covers the primary epilepsy and seizure disorder diagnoses that support levetiracetam administration. Payers crosswalk the J-code to the diagnosis code to confirm the drug is appropriate for the condition being treated.

Select the most specific code that reflects the documented diagnosis. Using G40.901 (epilepsy, unspecified) when the record documents a specific epilepsy type can attract payer audit attention.

The clinical notes must support the code selected, and the documentation should state why IV administration was chosen over oral therapy. The full ICD-10-CM code set lists the rest of the G40 subcategories if none of the six above matches the chart.

Place of service and clinical settings

Where J1953 is administered affects how claims are submitted and, in some cases, what rate Medicare pays. The three most common settings are the physician office, the hospital outpatient department, and the infusion center. Each has a distinct Place of Service (POS) code that must match the setting where the drug was given.

• POS 11 (Physician office): The most straightforward buy-and-bill setting. The practice acquires the drug, administers it, and bills J1953 on a CMS-1500 claim.
• POS 22 (On-campus outpatient hospital): The hospital facility bills the drug separately, and the physician may bill a professional component only. Coordinate with the facility billing team.
• POS 19 (Off-campus outpatient hospital): Similar to POS 22 but with different payment adjustments under Medicare’s outpatient prospective payment system.
• POS 14 (Homeless shelter) / POS 72 (Rural health clinic): Less common, but applicable when levetiracetam is given in these settings. Verify each payer’s policy.

Reimbursement can differ by setting. When the physician practice bills J1953 under Part B, Medicare pays the ASP plus 6% rate. Hospital outpatient settings may be paid under the outpatient prospective payment system instead. Confirm the applicable payment model with your MAC before you set up billing for a new site.

Buy-and-bill considerations for J1953

The buy-and-bill model means the practice purchases levetiracetam directly, administers it, and then bills the payer for both the drug and the administration. For J1953, this is the standard pathway in physician office and infusion center settings. The workflow has five steps, each carrying compliance risk if handled incorrectly.

1. Acquire the drug: Purchase levetiracetam from a licensed distributor. Maintain purchase invoices with lot numbers and NDC codes in case of an audit.
2. Verify coverage and prior authorization: Confirm the patient’s benefit and whether the payer requires PA before administration. PA denials after infusion are not reversible.
3. Administer and document: Record the dose in mg, route, infusion start and stop times, and the administering clinician. This documentation directly supports the unit count and modifier selection on the claim.
4. Calculate and submit the claim: Bill J1953 with the correct unit count, the route and wastage modifiers, the ICD-10 diagnosis code, and the POS code. Also bill the relevant administration CPT code (e.g. 96374 for IV push, 96365 for IV infusion).
5. Post the remittance: Match the remittance advice to the submitted claim. Flag any adjustments or denials for follow-up within your payer’s timely filing window.

Step four is where the rest of this guide converges. The worked example below turns one 1,000 mg dose into a complete claim line, field by field.

Prior authorization requirements

Medicare Part B generally does not require prior authorization for J1953, but commercial payers often do. PA requirements vary by plan, and some payers want documentation of treatment failure with oral antiepileptic drugs before approving the IV form.

When PA is required, submit a medical necessity letter covering the diagnosis, the rationale for IV administration, prescriber information, and the expected treatment duration. Keep a copy of every PA approval, including the authorization number, in the patient’s file.

If a PA is denied, a formal appeal with clinical documentation gives the best chance of reversal. Anti-kickback and fraud-and-abuse rules also apply to drug acquisition and billing under buy-and-bill, so review CMS compliance guidance before you set any markup strategy.

Related HCPCS and CPT codes

J1953 does not stand alone on most claims. It is typically submitted alongside an administration CPT code, and it may have crosswalk codes for situations where the drug is billed differently. Knowing the related code set helps practices build complete, accurate claims and avoid unbundling errors.

Using J3490 (unclassified drugs) after J1953 became active is a coding error that can delay or reduce reimbursement. Payers apply manual review to unclassified codes that they do not apply to specific J-codes. Confirm you are using the current active code through the NLM Clinical Table Search HCPCS API or the CMS HCPCS release files.

Common billing errors and how to avoid them

Four errors account for most J1953 rejections, and each one is visible in the claim before it goes out. The table below pairs each error with the check that prevents it.

A fifth error worth flagging is using J3490 (unclassified drugs) when J1953 is the correct active code. This happens when billing systems are not updated after a new J-code is added to the HCPCS schedule.

Claims submitted under J3490 for levetiracetam may be downpaid or denied as a coding error. Pair your annual code update review with a check of your drug billing templates. The currency check then happens once a year rather than claim by claim.

How Pabau supports J1953 claims and documentation

Entering a drug code by hand means working from two places at once. The dose sits in the clinical note, and the unit count belongs on the claim, so the number gets copied between systems.

Pabau, an all-in-one practice management system, keeps the appointment, the treatment note and the invoice on one patient record. Your team records the dose, the route and the infusion times in the note that supports the claim.

From there, Pabau’s claims management software pre-fills a claim from the data already on the record and submits it without a second system. You can check eligibility before the infusion date, follow claim status, and post remittances against the original claim. Your coder still chooses the code, the units and the modifier.

• One patient record: the dose, route and infusion times are recorded in the treatment note that sits alongside the invoice.
• Eligibility checks: confirm the patient’s benefit before the infusion date, so an authorization problem surfaces before the drug is drawn up.
• Pre-filled claims: claim lines are built from data already on the record, which removes a round of manual re-entry.
• Status and remittances: track what each claim is doing, and post remittance advice against the claim it belongs to.
• Reporting: see which claims came back unpaid, so your team can work them in one place instead of a spreadsheet.

The outcome is less re-keying between a chart and a claim form, and a shorter path from a documented dose to a paid claim.

Keep every infusion’s dose, note and claim together

Pabau keeps each infusion’s dose, treatment note and invoice on one patient record, then pre-fills and submits the claim from the data already there. Your coder still chooses the code and the units, with the documentation behind them one click away.

Book a demo

Conclusion

J1953 rewards a system over a memory. The unit math is trivial. It sits next to a modifier rule, a diagnosis link and a place-of-service code, and each one can sink the claim alone.

So the work worth doing sits upstream of the claim. Record the dose in milligrams at the point of administration, and settle each payer’s modifier rules once. The unit count and the wastage line then stop being a judgment call at submission time.

Pabau keeps the dose, the note and the invoice on one patient record, then pre-fills the claim from what is already there. Book a demo to see how a J-code claim moves from an infusion note to a submitted claim.

Continue your research

Want to understand how claims flow from submission to payment? What is medical billing explains the end-to-end claim lifecycle for outpatient practices.

Need to tighten your denial management process? Denial management in healthcare covers root cause analysis and appeal workflows for injectable drug claims.

Looking to verify eligibility before every infusion appointment? Insurance eligibility verification outlines a pre-service benefits check that catches authorization problems before the infusion date.

Frequently asked questions